Comparison of medical therapy with renal denervation in patients with resistant hypertension
Abstract
Introduction: Catheter-based renal denervation selectively reduces renal sympathetic efferent activity and is accompanied by an increase in renal blood flow and reduction in plasma renin activity. Thus, ablation of afferent and efferent renal nerves in patients with treatment-resistant hypertension probably leads to reductions in blood pressure.
Material and methods: The present study conducted a non-randomized case-control study and enrolled 15 patients who underwent renal denervation therapy for resistant hypertension as cases and 16 patients who were on medical management for resistant hypertension served as controls.
Results: It was found that catheter based renal denervation is safe, significantly reduces blood pressure at 1 month, 3 months and 6 months of follow-up without any major adverse events. It was observed that a significant BP reduction when compared to patients only on medical therapy. The mean number of drugs decreased significantly in the denervation group in follow-up.
Conclusions: Though the present study showed a significant BP reduction in patients with renal denervation, a significant effect on BP was not observed in a large randomized trial simplicity HTN-3 and major criticism was on the trials design and neuroscience failings. Even today the clinical dilemma is still continuing and further evaluation in rigorously designed clinical trials are necessary to validate alternative methods of renal denervation or to confirm previously reported benefits of renal denervation. The current study anticipate that future trials will also address the effectiveness of renal denervation in disease states other than hypertension.
Downloads
References
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circul. 2008;117(25):e510-e526. https://doi.org/10.1161/CIRCULATIONAHA.108.189141.
Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009;11(6):407. doi: https://doi.org/10.1007/s11886-009-0059-z.
Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev. 2010;90(2):607-673. doi: https://doi.org/10.1152/physrev.00011.2009.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427.
Textor SC. Revascularization in atherosclerotic renal artery disease. Kid Int. 1998;53 (3):799-811.
Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: The production of persistent ele¬vation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59(3):347-379. doi: https://doi.org/10.1084/jem.59.3.347.
Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg. 1941;114(4):753-755. doi: 10.1097/00000658-194111440-00018.
Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens. Off J Int Soc Hypertens. 1996;14(5):S159-S165.
Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90(2):513-557. doi: https://doi.org/10.1152/physrev.00007.2009.
Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertens. 2009;54(6):1195-1201. doi: https://doi.org/10.1161/HYPERTENSIONAHA.109.138610.
Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33(6):521-528. doi: https://doi.org/10.1038/hr.2010.35.
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet. 2009;373 (9671):1275-1281. doi: https://doi.org/10.1016/S0140-6736(09)60566-3.
Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F. Long-term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol. 2012;59(13):E1704. doi: 10.1016/S0735-1097(12)61705-7.
Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. The Lancet. 2014;383(9917):622-629. doi: https://doi.org/10.1016/S0140-6736(13)62192-3.
Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. The Lancet. 2010;376(9756):1903-1909. doi: https://doi.org/10.1016/S0140-6736 (10)62039-9.
Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, et al. Catheter‐based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN‐3 Trial. Clinical Cardiol. 2012;35(9):528-535. doi: https://doi.org/10.1002/clc.22008.
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. New Eng J Med. 2014;370(15):1393-1401. doi: 10.1056/NEJMoa1402670.
Persu A, Jin Y, Elmula FE, Renkin J, Høieggen A, Kjeldsen SE, et al. Renal denervation in treatment-resistant hypertension: a reappraisal. Curr Opi Pharmacol. 2015;21:48-52. https://doi.org/10.1016/j.coph.2014.12.013.
Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertens. 2015;65(6):1202-1208. doi: https://doi.org/10.1161/HYPERTENSIONAHA.115.05283.
Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. The Lancet. 2015;385(9981):1957-1965. doi: https://doi.org/10.1016/S0140-6736(14)61942-5.
Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertens. 2014;63(5):991-999. doi: https://doi.org/10.1161/HYPERTENSIONAHA.114.03246.
Rosa J, Widimský P, Toušek P, Petrák O, Čurila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertens. 2015;65(2):407-413. doi: https://doi.org/10.1161/HYPERTENSIONAHA.114.04019.
Agasthi P, Shipman J, Arsanjani R, Ashukem M, Girardo ME, Yerasi C, et al. Renal Denervation for Resistant Hypertension in the contemporary era: A Systematic Review and Meta-analysis. Sci Rep. 2019;9(1):6200. doi: https://doi.org/10.1038/s41598-019-42695-9.
Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593-598. doi: https://doi.org/10.1016/j.jash. 2014.06.001.
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Europe Heart J. 2014;36 (4):219-227. doi: https://doi.org/10.1093/eurheartj/ehu441.
Ram CV. Status of Renal Denervation Therapy for Hypertension: Still in Search of the Magic Bullet. Circulation. 2019;139(5):601-603. doi: https://doi.org/10.1161/circulationaha.118.037937.
Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, et al. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol. 2014;64(11):1079-1087. doi: 10.1016/j.jacc.2014.07.937.
OAI - Open Archives Initiative
